



# Correction to: A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa

Lethogonolo Makhele<sup>1</sup> · Moliehi Matlala<sup>1</sup> · Mncengeli Sibanda<sup>1</sup> · Antony P. Martin<sup>2,3</sup> · Brian Godman<sup>1,2,4,5</sup> 

© The Author(s) 2019

**Correction to: PharmacoEconomics - Open**  
<https://doi.org/10.1007/s41669-019-0124-5>

Multiple errors have been identified in the article including in the main findings.

For example, two sentences in the abstract, Results, which read:

“Variable costs (HD: US\$172, 359.15; PD: US\$20, 488.79) were found to be the biggest cost drivers for both treatment modalities. The annual cost of HD per patient (US\$205, 681.40) was higher than PD (US\$25, 282.00 per patient), even though the difference was not statistically significant ( $p = 0.175$ )”.

Should have read:

“Fixed costs were the principal cost driver for HD (\$16,231.45) while variable costs were the principal cost driver for PD (US\$20,488.79). The annual cost of HD per patient (US\$31,993.12) was higher than PD (US\$25,282.00 per patient), even though the difference was not statistically significant ( $p = 0.816$ )”.

Errors were also identified in the following locations:

- Section “3 Results”
- Section “4 Discussion”
- Table 1
- Table 3
- Figure 2
- Table 6
- Section “5 Conclusion”

The article has now been updated to correct the errors.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s41669-019-0124-5>.

✉ Brian Godman  
Brian.Godman@strath.ac.uk; Brian.Godman@ki.se

Lethogonolo Makhele  
makhele.nolo@gmail.com

Moliehi Matlala  
moliehi.matlala@smu.ac.za

Mncengeli Sibanda  
mncengelisi@gmail.com

Antony P. Martin  
a.p.martin@liverpool.ac.uk;  
antony.martin@hcdconomics.com

- <sup>1</sup> Department of Public Health and Pharmacy Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa
- <sup>2</sup> Health Economics Centre, University of Liverpool Management School, Chatham Street, Liverpool, UK
- <sup>3</sup> HCD Economics, The Innovation Centre, Daresbury WA4 4FS, UK
- <sup>4</sup> Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK
- <sup>5</sup> Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden